---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029955"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:26:39.091085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nkarta NKX101 achieves 67% CR/CRi in AML Phase 1 with modified lymphodepletion

## Summary
- In Flu/Ara-C cohort (n=6), NKX101 showed 67% CR/CRi rate (4/6) and 50% CR rate (3/6); 2 CRs MRD-negative.
- In Flu/Cy highest-dose cohort (n=18), CR/CRi rate was 22% (4/18) and CR rate 17% (3/18).
- NKX101 well tolerated; no dose-limiting toxicities, limited CRS/ICANS/GvHD across all doses.
- Expansion cohort with Flu/Ara-C to enroll 12-20 more patients; clinical update expected 1H 2024.
- Patients heavily pre-treated (median 2 prior lines, 90%+ prior venetoclax); majority poor-risk disease.

## SEC filing metadata
- accession: 0000950170-23-029955
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017023029955/0000950170-23-029955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017023029955/nktx-20230627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029955
- JSON: https://secwatch.observer/filing/0000950170-23-029955.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.